Breaking News

Sanofi Invests €170M in New Vaccine Facility in France

Will allow Sanofi Pasteur to expand the global supply of its new quadrivalent influenza vaccine VaxigripTetra

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Sanofi is investing €170 million to expand a vaccine manufacturing site in Val de Reuil, France. The new facility will allow Sanofi Pasteur, the Vaccines unit of Sanofi, to expand the global supply of its new quadrivalent influenza vaccine, VaxigripTetra. The new vaccine contains two A strains and two B strains of influenza virus, as per World Health Organization recommendation. Sanofi plans to complete the expansion by 2021, and begin producing vaccines at this site in 2022. “This proj...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters